dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Chen, Li T. |
dc.contributor.author | Macarulla Mercadé, Teresa |
dc.contributor.author | Blanc, Jean-Frédéric |
dc.contributor.author | Mirakhur, Beloo |
dc.contributor.author | Jong, Floris A. de |
dc.contributor.author | Belanger, Bruce |
dc.date.accessioned | 2020-02-20T14:04:08Z |
dc.date.available | 2020-02-20T14:04:08Z |
dc.date.issued | 2019-07-28 |
dc.identifier.citation | Chen LT, Macarulla T, Blanc JF, Mirakhur B, Jong FA, Belanger B, et al. Nomogram for predicting survival in patients treated with liposomal irinotecan plus fluorouracil and leucovorin in metastatic pancreatic cancer. Cancers. 2019 Jul 28;11(8):1068. |
dc.identifier.issn | 2072-6694 |
dc.identifier.uri | https://hdl.handle.net/11351/4669 |
dc.description | NAPOLI-1; Irinotecan liposòmic; Resultats de supervivència |
dc.description.sponsorship | This study (NCT01494506) was supported by Merrimack Pharmaceuticals, Inc., Cambridge, MA, USA. Analysis sponsored by Ipsen Biopharmaceuticals, Inc., Basking Ridge, NJ, USA. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Cancers;11(8) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Nomografia (Matemàtica) |
dc.subject | Pàncrees - Càncer |
dc.subject | Medicaments antineoplàstics |
dc.subject.mesh | Nomograms |
dc.subject.mesh | Neoplasm Metastasis |
dc.subject.mesh | /Pancreas |
dc.subject.mesh | Antineoplastic Agents |
dc.title | Nomogram for predicting survival in patients treated with liposomal irinotecan plus fluorouracil and leucovorin in metastatic pancreatic cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/cancers11081068 |
dc.subject.decs | nomogramas |
dc.subject.decs | metástasis neoplásica |
dc.subject.decs | /Páncreas |
dc.subject.decs | antineoplásicos |
dc.relation.publishversion | https://www.mdpi.com/2072-6694/11/8/1068 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.authoraffiliation | [Chen LT ] National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan. Division of Hematology/Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan. [Macarulla T] Hospital Universitari Vall d’Hebron, Barcelona, Spain. Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain. [Blanc JF] Groupe Hospitalier Haut-Lévêque, CHU Bordeaux, Pessac, France. [Mirakhur B] Ipsen Biopharmaceuticals, Inc., Basking Ridge, USA. [Jong FA] Global Medical Affiars, Servier, Zürich, Switzerland. [Belanger B] Ipsen Biopharmaceuticals, Inc., Cambridge, USA |
dc.identifier.pmid | 31357748 |
dc.identifier.wos | 000484438000028 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |